Biotech 2024: Opportunities and challenges for Israeli companies
22.01.24|Tomer Bronshtein
“Despite their strong clinical data and established R&D programs, Israeli biotech companies are undervalued. Following two years of economic downturn, these companies now present attractive investment opportunities,” writes Dr. Tomer Bronshtein, VP for Innovation and Corporate Development at Bonus Biogroup